Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note published on Saturday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock opened at $0.05 on Friday. The stock has a 50 day simple moving average of $0.06 and a 200-day simple moving average of $0.06. The company has a market cap of $623,730.00, a price-to-earnings ratio of -0.06 and a beta of 0.73. Bellerophon Therapeutics has a 12-month low of $0.03 and a 12-month high of $0.52.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.